Cargando…

Impact of tanezumab on health status, non-work activities and work productivity in adults with moderate-to-severe osteoarthritis

BACKGROUND: To evaluate the impact of tanezumab on health status, non-work activities, and work productivity in a pooled analysis of two large phase 3 osteoarthritis (OA) studies. METHODS: Subcutaneous tanezumab (2.5 mg and 5 mg) was tested in double-blind, placebo-controlled, 16-week (NCT02697773)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Conaghan, Philip G., Abraham, Lucy, Viktrup, Lars, Cislo, Paul
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8809015/ https://www.ncbi.nlm.nih.gov/pubmed/35105318 http://dx.doi.org/10.1186/s12891-022-05029-x

Ejemplares similares

Single and Composite Endpoints of Within-Patient Improvement in Symptoms: Pooled Tanezumab Data in Patients with Osteoarthritis
por: Schnitzer, Thomas J., et al.
Publicado: (2021)

Subcutaneous tanezumab for osteoarthritis: Is the early improvement in pain and function meaningful and sustained?
por: Berenbaum, Francis, et al.
Publicado: (2021)

Response to: “Tanezumab: Therapy targeting nerve growth factor in pain pathogenesis”
por: Tive, Leslie A., et al.
Publicado: (2018)

General Safety and Tolerability of Subcutaneous Tanezumab for Osteoarthritis: A Pooled Analysis of Three Randomized, Placebo‐Controlled Trials
por: Berenbaum, Francis, et al.
Publicado: (2022)

Tanezumab for Patients with Osteoarthritis of the Knee: A Meta-Analysis
por: Kan, Shun-Li, et al.
Publicado: (2016)

Gender, age, disease severity, body mass index and diabetes may not affect response to subcutaneous tanezumab in patients with osteoarthritis after 16 weeks of treatment. A subgroup analysis of placebo‐controlled trials
por: Berenbaum, Francis, et al.
Publicado: (2021)

Safety and efficacy of subcutaneous tanezumab in patients with knee or hip osteoarthritis
por: Birbara, Charles, et al.
Publicado: (2018)

Observed efficacy and clinically important improvements in participants with osteoarthritis treated with subcutaneous tanezumab: results from a 56-week randomized NSAID-controlled study
por: Neogi, Tuhina, et al.
Publicado: (2022)

Time to first and sustained improvement in WOMAC domains among patients with osteoarthritis receiving tanezumab
por: Hunter, D.J., et al.
Publicado: (2022)

Population pharmacokinetics of tanezumab in phase 3 clinical trials for osteoarthritis pain
por: Jonsson, E. Niclas, et al.
Publicado: (2016)

Subcutaneous tanezumab for osteoarthritis of the hip or knee: efficacy and safety results from a 24-week randomised phase III study with a 24-week follow-up period
por: Berenbaum, Francis, et al.
Publicado: (2020)

Clinical Outcomes of Tanezumab With Different Dosages for Patient With Osteoarthritis: Network Meta-Analysis
por: Hu, Rui, et al.
Publicado: (2021)

Relative Efficacy and Safety of Tanezumab for Osteoarthritis: A Systematic Review and Meta-analysis of Randomized-Controlled Trials
por: Zhang, Bocheng, et al.
Publicado: (2021)

Tanezumab for chronic low back pain: a randomized, double-blind, placebo- and active-controlled, phase 3 study of efficacy and safety
por: Markman, John D., et al.
Publicado: (2020)

Clinical Meaningfulness of Response to Tanezumab in Patients with Chronic Low Back Pain: Analysis From a 56-Week, Randomized, Placebo- and Tramadol-Controlled, Phase 3 Trial
por: Markman, John D., et al.
Publicado: (2022)

Tanezumab: Finally a Monoclonal Antibody for Pain Relief
por: Nair, Abhijit S
Publicado: (2018)

Burden of chronic low back pain: Association with pain severity and prescription medication use in five large European countries
por: Perrot, Serge, et al.
Publicado: (2021)

Tanezumab: Therapy targeting nerve growth factor in pain pathogenesis
por: Patel, Mona K., et al.
Publicado: (2018)

First-in-human randomized clinical trials of the safety and efficacy of tanezumab for treatment of chronic knee osteoarthritis pain or acute bunionectomy pain
por: Walicke, Patricia A., et al.
Publicado: (2018)

Pooled analysis of tanezumab efficacy and safety with subgroup analyses of phase III clinical trials in patients with osteoarthritis pain of the knee or hip
por: Tive, Leslie, et al.
Publicado: (2019)

Pooled Analysis of Tanezumab Efficacy and Safety with Subgroup Analyses of Phase III Clinical Trials in Patients with Osteoarthritis Pain of the Knee or Hip [Corrigendum]
Publicado: (2020)

Efficacy, General Safety, and Joint Safety of Tanezumab in Japanese Patients with Osteoarthritis: Subgroup Analyses from Two Randomized, Phase 3 Studies
por: Miki, Kenji, et al.
Publicado: (2022)

Based on minimal clinically important difference values, a moderate dose of tanezumab may be a better option for treating hip or knee osteoarthritis: a meta-analysis of randomized controlled trials
por: Zhao, Di, et al.
Publicado: (2022)

Tanezumab: a selective humanized mAb for chronic lower back pain
por: Webb, Michael P, et al.
Publicado: (2018)

Factors associated with physician-reported treatment status of patients with osteoarthritis pain
por: Schnitzer, Thomas J., et al.
Publicado: (2022)

Prospects for Therapies in Osteoarthritis
por: Ghouri, Asim, et al.
Publicado: (2020)

Activity Impairment, Work Status, and Work Productivity Loss in Adults 5–7 Years After Burn Injuries
por: Spronk, Inge, et al.
Publicado: (2021)

Relationship between patient-reported disease severity in osteoarthritis and self-reported pain, function and work productivity
por: Sadosky, Alesia B, et al.
Publicado: (2010)

Relationship of insurance type and treatment of severe status asthmaticus in working-age adults
por: Wood, K, et al.
Publicado: (2004)

Update on novel pharmacological therapies for osteoarthritis
por: Ghouri, Asim, et al.
Publicado: (2019)

Synovitis in osteoarthritis: current understanding with therapeutic implications
por: Mathiessen, Alexander, et al.
Publicado: (2017)

Cognitive Activity as a Moderator of Educational Attainment and Work Status in Cognitive Aging
por: Stieger, Mirjam, et al.
Publicado: (2020)

Meaningful work, pleasure in working, and the moderating effects of deep acting and COVID‐19 on nurses' work
por: Pace, Francesco, et al.
Publicado: (2022)

An Observational Retrospective Matched Cohort Study of Healthcare Resource Utilisation and Costs in UK Patients with Moderate to Severe Osteoarthritis Pain
por: Abraham, Lucy, et al.
Publicado: (2022)

GRANDPARENTING AND DEPRESSIVE SYMPTOMS IN URBAN CHINA: LIVING ARRANGEMENTS AND WORK STATUS AS MODERATING EFFECTS
por: Ma, Luyan, et al.
Publicado: (2022)

New developments in osteoarthritis pharmacological therapies
por: Ghouri, Asim, et al.
Publicado: (2021)

Various Doses of Tanezumab in the Management of Chronic Low Back Pain (CLBP): A Pooled Analysis of 4,514 Patients
por: Tahir, Sophia, et al.
Publicado: (2023)

Work Engagement and Flourishing at Work Among Nuns: The Moderating Role of Human Values
por: Ariza-Montes, Antonio, et al.
Publicado: (2018)

Work Stressors and Occupational Health of Young Employees: The Moderating Role of Work Adaptability
por: Zhou, Houyu, et al.
Publicado: (2022)

Quality of Work Life and Contribution to Productivity: Assessing the Moderator Effects of Burnout Syndrome
por: Leitão, João, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_dlhhrlcb19n4q2l1hea9frv28m